Sponsored by:
Hewlett Packard (HPQ)
Dell (DELL)
Facebook (FB)
Apple (AAPL)
Focus Stocks
Featured Stories
Fred's First Quarter 2012 EPS Increase 17%
Newell Rubbermaid to Reaffirm Fiscal Year 2012 Outlook
Best ETFs For Facebook Exposure
McDonald's Announces Quarterly Cash Dividend
Is KB HOME Closing in to Resistance?
Is Amgen Breaking Out?
Published on Monday, 23 January 2012 07:20 Written by Christian Paolinetti
New York, January 23rd (TradersHuddle.com) - Shares of Amgen Inc. (NASDAQ:AMGN) closed the trading session at $69.57 just above calculated resistance at $67.78 effectively breaking out, grabbing the attention of momentum traders, which could eventually push the stock to different trading range
Amgen Inc. (NASDAQ:AMGN) develops, manufactures, and markets human therapeutics based on cellular and molecular biology. The company concentrates on the areas of hematology, cancer, infectious disease, endocrinology, neurobiology, and inflammation.
Amgen's stock was trading in a well defined range with support at $56.00 and resistance at $67.78, given that this range was broken traders will be closely monitoring the stock
Related Articles
- Approaching Resistance: Amgen
- Amgen Is Close to the 50 Day Moving Average
- Amgen Is Close to the 50 Day Moving Average
- Amgen Is Close to Resistance
- Amgen Is Close to the 50 Day Moving Average
- Approaching Resistance: Amgen
- Amgen Broke Resistance
- Is Amgen Closing in to Resistance?
- Biotech Laggard
- Is Amgen Closing in to Resistance?
Related Partner Headlines
- Amgen Inc (AMGN): Today's Featured Drugs Loser - TheStreet.com
- From Earlier: Amgen Announces Analysis Of Rilotumumab Data Identifies A Potential Predictive Biomarker For Patients With Gastric Or Gastroesophageal Cancer - Benzinga
- From Earlier: Amgen Announces Analysis Of Rilotumumab Data Identifies A Potential Predictive Biomarker For Patients With Gastric Or Gastroesophageal Cancer - Benzinga
- From Earlier: Amgen Announces Analysis Of Rilotumumab Data Identifies A Potential Predictive Biomarker For Patients With Gastric Or Gastroesophageal Cancer - Benzinga
- Amgen Stock To Go Ex-dividend Monday (AMGN) - TheStreet.com
- Amgen Inc (AMGN): Today's Featured Drugs Winner - TheStreet.com
- Amgen Reaches New 52-Week High (AMGN) - TheStreet.com
- Benzinga's M&A Chatter for Wednesday April 25, 2012 - Benzinga
- Amgen Goes to Turkey, Loses Biotech Cred - TheStreet.com
- From Earlier: Amgen to Acquire Mustafa Nevzat; Company Valued at $700M - Benzinga
What’s the next under-$10 stock that could be ready to skyrocket? Find out now when you join David Peltier at Stocks Under $10.
TradersHuddle Search
| Sponsored By:
|
|
Stock Search: |
|
Site Search: Loading
|
Recent Trading Ideas
Latest Partner Headlines
Stock Market
Loading
